SCHEMBL648864

SCHEMBL648864

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccc2c(c1)CCN2C

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
TSHR P16473 2/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913061 0.89 C5AR1 (0.38) C5AR1ALDH1A1HTT
SCHEMBL651033 0.88 C5AR1 (0.44) C5AR1ALDH1A1HTTTSHR
SCHEMBL651956 0.87 C5AR1 (0.43) C5AR1ALDH1A1HTTTSHR
SCHEMBL649152 0.86 C5AR1 (0.47) C5AR1
SCHEMBL648790 0.86 C5AR1 (0.43) C5AR1ALDH1A1HTTTSHR
SCHEMBL650580 0.85 C5AR1 (0.41) C5AR1ALDH1A1HTTTSHR
SCHEMBL5135971 0.85 C5AR1 (0.41) C5AR1ALDH1A1HTTTSHR
SCHEMBL652505 0.84 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHR
SCHEMBL648409 0.84 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHR
SCHEMBL649675 0.84 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306152-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LBORATORIES, INC. (US) 2008-12-11 US claimed
EP-1651202-A4 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LAB INC (US) 2006-08-02 EP claimed
EP-1651202-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2006-05-03 EP claimed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO claimed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US claimed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119667-B2 Carbonates of fenicol antibiotics SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2012-02-21 US disclosed
EP-1966129-B1 CARBONATES OF FENICOL ANTIBIOTICS SCHERING PLOUGH LTD (CH) 2011-08-17 EP disclosed
US-7786167-B2 Ester derivatives; in vivo saponification by endogenous enzymes; dosage efficiency IDEXX LABORATORIES, INC. (US) 2010-08-31 US disclosed
US-7786167-B2 Ester derivatives; in vivo saponification by endogenous enzymes; dosage efficiency IDEXX LABORATORIES, INC. (US) 2010-08-31 US disclosed
EP-1651202-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2006-05-03 EP disclosed
EP-1651202-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2006-05-03 EP disclosed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO disclosed
WO-2005009429-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE IDEXX LABORATORIES, INC. (US) 2005-02-03 WO disclosed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US disclosed
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use IDEXX LABORATORIES, INC. 2005-01-20 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306152-A1 COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE FAP, CYP3A5, CYP4F3 C5AR1 1670/4885ALDH1A1 178/4885HTT 3093/4885
US-20050014828-A1 Compositions containing prodrugs of florfenicol and methods of use FAP, CYP3A5, CYP4F3 C5AR1 1670/4885ALDH1A1 178/4885HTT 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.